Accessibility links Skip to main content

eQMS Implementation and 4 points to consider

Prior to delving into the recommendations, it is critical to underscore that the implementation of an electronic Quality Management System (eQMS) represents a substantial and high-risk endeavour. Nevertheless, the long-term benefits will significantly outweigh the initial challenges.

Contact us

Fill out the form and we will contact you shortly.

Naam
Privacy Policy 
Continue reading

Although numerous articles describe the standard procedures for transitioning from paper-based systems to an eQMS, and vendors of these systems provide valuable insights on their websites, it is important to consider several additional factors that may assist organisations in this new phase of their operational processes.

Most commercially available systems will involve a validation phase and customer onboarding as part of their service offerings. However, the starting point must be a User Requirement Specification defining the requirements of the system to meet the specific requirements of the organization. This should be generated by team members with appropriate experience or by leveraging external support.

Here are some additional points that may assist you in addressing previous challenges and ensuring alignment with your supplier in the phase preceding implementation:

Point 1 – Change Control

It goes without saying that the introduction of an eQMS in any organisation is a critical change in the operations and so must be managed and controlled accordingly. One of the first steps must be to raise a detailed change control establishing the pre and post implementation actions for the system, the action owners and any effectiveness checks that may be required. The change needs to be assessed by all stakeholders to verify that all potential areas of impact have been considered and documented.

Point 2 – Supplier engagement and experience

When engaging with your supplier, it is essential to ascertain whether they employ professionals with training and experience in the pharmaceutical industry. This inquiry is crucial to ensure that the engineering team is adequately prepared to address your questions during the implementation phase as it is important that these inquiries do not come as a surprise to them.

Point 3 – Sandbox testing

During the preliminary functionality checks of the system, typically conducted in a sandbox environment by the internal team, it is important to establish if the system is capable or replicating your internal process per your SOP.

Point 4: System support and Service Level Agreements/Quality Technical Agreements

It’s important to evaluate the response times for issues raised with the system (should any arise) and the methods used to request assistance from the technical team. While your vendor may offer information on response times based on different levels of complexity, it is advisable to specify such response times in one or both of a Service Level Agreement or Quality Technical Agreement.

MIAS has recently implemented its own eQMS for the management of all our internal systems. We are more than happy to share and discuss our experience and knowledge gained in order to support you on your eQMS implementation journey.

Your partner in quality, safety, and compliance

The life sciences sector requires specialized knowledge and reliable support. With our broad expertise, we help organizations comply with laws and regulations, ensure quality, and continue to innovate with confidence.

Related services

QP Services

Clinical QP Services

Related articles

07 Apr 2026

MIAS Pharma will be attending the BIO International Convention in San Diego, USA

MIAS Pharma is excited to attend the BIO International convention in San Diego, California, from June 22nd – 25th 2026. Visit us at booth #4052, we’ll be happy to connect.

01 Apr 2026

Let’s Meet at SNMMI Annual meeting 2026 LA

MIAS Pharma is excited to attend the SNMMI annual meeting in Los Angeles, California, from May 30th – June 2nd 2026. Visit us at booth #1363, we’ll be happy to connect.

20 Mar 2026

Labelling & Packaging: A Core MAH Responsibility

Marketing Authorisation Holders (MAHs) carry primary responsibility for the accuracy, control, and lifecycle management of labelling and packaging across all markets where a product is placed on the EU/EEA market. This obligation extends beyond artwork creation to encompass regulatory approval, change control, supply chain implementation, and post‑market vigilance for labelling‑related quality defects and recalls.

06 Mar 2026

MAHs: Are Your GMP–GVP Interfaces Aligned?

Calling all Marketing Authorisation Holders (MAHs) are you set up for success? Have you confirmed whether your five‑year renewal is required? Is this critical information visible and accessible to your QPs and QPPVs?

27 Feb 2026

MIAS Pharma: End to End MAH services for Virtual and Rare Disease Companies

For small and virtual companies, especially those developing rare disease medicines, the requirements of acting as a Marketing Authorisation Holder (MAH) in the EU can feel overwhelming. EU legislation places the MAH at the centre of responsibility for the quality, safety and efficacy of the product throughout its lifecycle, regardless of how many activities are outsourced. MIAS Pharma is designed to be your one integrated partner in Europe: an established presence with the expertise, infrastructure and network to assume day‑to‑day MAH obligations on your behalf while you focus on science, patients and portfolio strategy.

20 Feb 2026

Quality & Regulatory Implications from EU Critical Medicines Act

The European pharmaceutical landscape is entering a period of major regulatory transformation with the introduction of not only the EU Critical Medicines Act (CMA), new pharma package.

28 Jan 2026

Navigating Evolving EU Marketing Authorisation: Are You Ready for Tomorrow’s Compliance?

As the European pharmaceutical landscape transforms, Marketing Authorisation Holders (MAHs) now face a broader – and more demanding – array of duties that stretch far beyond initial product approval. The new compliance reality encompasses critical operational areas like shortage reporting, environmental risk management, end-to-end product data maintenance, supply chain resilience, and more. These obligations often overlap with, yet are legally distinct from, manufacturing and wholesale authorisations – presenting new blind spots and risks for the unprepared.